Satsuma Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
STSA Nasdaq 8731 https://www.satsumarx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine - May 18th, 2023 8:01 pm
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting - Apr 21st, 2023 12:00 pm
SNBL to Acquire Satsuma Pharmaceuticals - Apr 16th, 2023 11:41 pm
We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Rate - Mar 30th, 2023 10:07 am
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights - Mar 28th, 2023 8:05 pm
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference - Feb 2nd, 2023 1:00 pm
Despite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For Approval - Dec 20th, 2022 5:46 pm
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update - Dec 20th, 2022 2:21 pm
As Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) gains 14%, insiders who bought last year may be wishing they had bet higher - Nov 30th, 2022 12:02 pm
Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference - Nov 23rd, 2022 6:59 pm
Satsuma Pharma Shares Nosedives After Disappointing Data From Migraine Study - Nov 14th, 2022 1:55 pm
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine - Nov 14th, 2022 12:00 pm
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Nov 3rd, 2022 8:05 pm
Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation - Oct 20th, 2022 7:24 pm
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study - Sep 28th, 2022 5:13 pm
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size - Sep 28th, 2022 5:11 pm
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate - Sep 27th, 2022 4:35 pm
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold - Sep 23rd, 2022 2:57 pm
This Stock Earns Price Bump, Bullish Pitch On Recent Positive Migraine Drug Data - Sep 21st, 2022 6:33 pm
Wave Therapeutics (WVE) Up on Update From Huntington's Study - Sep 21st, 2022 3:39 pm